Parkinson's disease (PD) is a relentlessly growing neurodegenerative disorder clinically
manifested by rigidity, tremors, and dyskinesia ascribed to loss of nigrostriatal dopaminergic …

Background Parkinson's disease (PD) is the second most common neurodegenerative
disease with a significant public health burden. It is characterized by the gradual …

Parkinson disease (PD) is a progressive movement disorder marked by tremor, rigidity,
bradykinesia and postural instability. Levodopa (l‐dopa), usually combined with a peripheral …

Parkinson's disease (PD)-related phenotypes can vary among patients substantially,
including response to dopaminergic treatment in terms of efficacy and occurrence of adverse …

Parkinson's disease (PD) is a chronic progressive neurodegenerative brain disorder
presenting with motor signs and symptoms, such as akinesia, rest tremor, rigidity, and later …

Introduction: There is a considerable inter-individual heterogeneity in clinical features,
disease course, and treatment response in Parkinson's disease (PD), which can be …

Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder for which
no restorative or neuroprotective therapy is available. Interest has recently been directed to …

Aim: L-dopa remains the most effective symptomatic therapy for Parkinson's disease (PD)
but unfortunately, its chronic use is often associated with motor complications. This review …

Introduction Parkinson's disease is a chronic neurodegenerative multisystemic disorder that
affects approximately 2% of the population over 65 years old. This disorder is characterized …

Parkinson's disease (PD) is a debilitating, demoralizing and financially devastating condition
affecting 1% of population at the age of 60 years. Thus, very important issue to address is …